Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann C Collier

Showing results (61-70 of 184) with videos related to

Pageof 19
Sort By:
AIDS (London, England)|January 27, 2007
Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimenMargaret A Fischl, Ann C Collier, A Lisa Mukherjee, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 24, 2011
No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRTHeather J Ribaudo, Constance A Benson, Yu Zheng, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 11, 2015
Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging StudyLi Liu, Ann C Collier, Jeanne M Link, et al.
AIDS (London, England)|July 14, 2011
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapyRonald J Ellis, Jayraan Badiee, Florin Vaida, et al.
AIDS (London, England)|January 26, 2005
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 resultsAngela Dm Kashuba, Camlin Tierney, Gerald F Downey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 6, 2007
Screening for acute HIV infection: lessons learnedJoanne Stekler, Janine Maenza, Claire E Stevens, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 15, 2013
Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiationPhilip M Grant, Douglas Kitch, Grace A McComsey, et al.
The Journal of Infectious Diseases|December 4, 2012
Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202Grace A McComsey, Eric S Daar, MaryAnn O'Riordan, et al.
HIV Clinical Trials|May 14, 2008
Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIVAnn C Collier, Camlin Tierney, Gerald F Downey, et al.
The Journal of Infectious Diseases|June 23, 2016
Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected IndividualsPhilip M Grant, Douglas Kitch, Grace A McComsey, et al.
Pageof 19

Showing results (61-70 of 184) with videos related to

Sort By:
Pageof 19
AIDS (London, England)|January 27, 2007
Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimenMargaret A Fischl, Ann C Collier, A Lisa Mukherjee, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 24, 2011
No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRTHeather J Ribaudo, Constance A Benson, Yu Zheng, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|September 11, 2015
Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging StudyLi Liu, Ann C Collier, Jeanne M Link, et al.
AIDS (London, England)|July 14, 2011
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapyRonald J Ellis, Jayraan Badiee, Florin Vaida, et al.
AIDS (London, England)|January 26, 2005
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 resultsAngela Dm Kashuba, Camlin Tierney, Gerald F Downey, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 6, 2007
Screening for acute HIV infection: lessons learnedJoanne Stekler, Janine Maenza, Claire E Stevens, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 15, 2013
Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiationPhilip M Grant, Douglas Kitch, Grace A McComsey, et al.
The Journal of Infectious Diseases|December 4, 2012
Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202Grace A McComsey, Eric S Daar, MaryAnn O'Riordan, et al.
HIV Clinical Trials|May 14, 2008
Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIVAnn C Collier, Camlin Tierney, Gerald F Downey, et al.
The Journal of Infectious Diseases|June 23, 2016
Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected IndividualsPhilip M Grant, Douglas Kitch, Grace A McComsey, et al.
Pageof 19